Andrew Mignatti

Director & CEO

Andrew is an accomplished molecular diagnostics industry professional, having spent over 20 years in the field.

Andrew began his career at Allergy Testing Laboratory and became the regional director of sales before the company was ultimately acquired by LabCorp. As the director of business development at LabCorp, Andrew gained valuable insight into the operations of a major laboratory as he led the company through multiple successful acquisitions in his division.

Prior to careviso, Andrew held executive leadership roles for molecular diagnostics companies, RedPath Integrated Pathology (now Interpace Diagnostic) and then was the CEO for Perthera. At Perthera, Andrew successfully raised $10 million in capital funding and doubled the company’s revenue during his tenure, taking it from a small start-up to a fully operating business.

Since founding careviso in 2017, Andrew has delivered extraordinary results in a short period of time. He has built a fully functioning proprietary automated software system and partnered with over 60 clients and/or laboratories. His vision is to solve the most complex problems in the healthcare industry in real-time: financial transparency and prior authorizations. 

careviso created a complete technology platform that increases patient access to care by delivering cost estimates, administrative requirements and approvals in real time. careviso began with a laboratory-focused approach, and the mission is to support everyone involved in healthcare.

Book your software demo

Discover how seeQer informs patients and transforms practice.

Schedule a seeQer demonstration of benefits verifications, cost assessments, and other essential tasks in the platform. Learn how seeQer can help your organization reduce administrative burden, transform cumbersome processes, and provide transparency that empowers patients in a complex and ever-changing industry.